Compare FUND & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | IMMX |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.7M | 306.2M |
| IPO Year | N/A | 2021 |
| Metric | FUND | IMMX |
|---|---|---|
| Price | $9.86 | $7.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 32.5K | ★ 936.9K |
| Earning Date | 01-01-0001 | 03-24-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.75 | $1.34 |
| 52 Week High | $8.47 | $7.73 |
| Indicator | FUND | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 67.89 |
| Support Level | $9.41 | $6.02 |
| Resistance Level | $9.96 | $7.04 |
| Average True Range (ATR) | 0.15 | 0.58 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 64.70 | 97.16 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.